The MedTech Funding Mandate (MTFM) is an NHS Long Term Plan commitment to give patients access to selected NICE approved, cost-efficient technologies more quickly.
To be considered for inclusion technologies needed to be:
This mandate piloted four former Innovation and Technology Payment (ITP) products from 1st April 2021. The chosen products are NICE approved and were selected as they met the criterion of being effective, cost-saving, affordable and capable of delivering material savings to the NHS and will continue to be supported in 2022/23.
The four products are:
A number of technologies have also been selected for inclusion in the 2022/23 policy which are categorised into two themes:
This is a common condition in ageing men and others with a prostate (trans women, some non-binary and some intersex people). It is currently treated with the surgical procedure, transurethral resection of the prostate (TURP) which usually requires the patient to stay in hospital for 1 to 3 days. Four less invasive innovations allow patients with BPH to be treated as day cases. Providers will not be expected to implement all four technologies, instead, each would be expected to work with its AHSN and the Getting It Right First Time (GIRFT) Urology Area Networks to understand its technology needs and the potential uptake locally.The following four innovations allow patients with BPH to be treated as day cases. NHS providers will not be expected to implement all four technologies, instead, each is expected to work with Health Innovation East and the Getting It Right First Time (GIRFT) Urology Area Networks to understand its technology needs and the potential uptake locally.
We are working with suppliers to support trusts to implement the selected innovations, understand local and regional issues and share learnings from NHS organisations who have already implemented these innovations. This will help us identify any barriers to their uptake, such as duplicative procurement processes.
NHS providers are expected to comply with the policy guidance and we will work closely with providers, clinicians, patient groups and commissioners to understand the impact of the policy and support its development.
This workstream includes:
Med Tech Funding Mandate products are not centrally funded. NHS-funded care providers and commissioners are expected to fund and develop local agreements and comply with the mandate.
For more information you can watch Matt Whitty, Director of Innovation, Research and Life Sciences and Chief Executive of AAC and other policy leaders, discussing the MedTech Funding Mandate policy’s introduction. The videos provide an overview of the policy and the financial flow between NHS England and NHS Improvement, Trusts and CCGs. You can read more in the NHS MedTech Funding Mandate
policy 2022/23: Guidance for NHS commissioners and providers of NHS-funded care.
We are looking to work with the system, healthcare professionals and patients to maximise the benefit of this initiative as follows:
We would like you to work with us to create awareness of the policy, become familiar with the selected technologies, help us understand the current and projected level of technology uptake and identify the patient population in your locality who could benefit.
We’d love to work with healthcare professionals who have experience of using these technologies to provide a peer-to-peer network, sharing of best practices and where appropriate, resources to improve efficiencies.
If you been treated using any of the MedTech Funding Mandate technologies we would like to better understand your experiences and can share these with others who might be starting their treatment.
For further information please contact:
Ben Jackson, Advisor on 01223 661 498 or Ben.Jackson@healthinnovationeast.co.uk.
Do you have a great idea that could make a positive health impact?Get involved